Immunai

Immunai is a biotechnology company that applies machine learning to single cell data in order to map the human immune system and support drug discovery and development. Its product is the Immunai Operating System, a workflow that biopharmaceutical companies and research institutions use through partnership rather than self service sign up. The platform works in five steps. It generates multiomic single cell data from clinical and preclinical samples, augments that data with AMICA, which the company describes as the largest immune focused harmonized single cell database, computes immune features with machine learning that link mechanisms to treatment response, validates the resulting hypotheses in the lab with functional genomics, and finally produces recommendations on how to proceed. These are organized into three solution areas: target discovery, preclinical evaluation, and clinical trial optimization, which covers patient stratification, dose selection, drug mechanism of action and combination prioritization. It is meant for pharmaceutical and biotech teams making decisions about targets, candidates and trial design. The company names collaborations with AstraZeneca, on inflammatory bowel disease target discovery, and Teva, on vitiligo mechanism and biomarker discovery. Immunai was founded in December 2018, is headquartered in New York with offices in Tel Aviv, Prague and Zurich, and built AMICA partly through the 2021 acquisitions of Dropprint Genomics and Nebion. Pricing is not published. Engagements are arranged through the company's partnership contact.